| __timestamp | CRISPR Therapeutics AG | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 26684000 |
| Thursday, January 1, 2015 | 13403000 | 29829000 |
| Friday, January 1, 2016 | 31056000 | 39578000 |
| Sunday, January 1, 2017 | 35845000 | 43277000 |
| Monday, January 1, 2018 | 48294000 | 48645000 |
| Tuesday, January 1, 2019 | 63488000 | 52934000 |
| Wednesday, January 1, 2020 | 88208000 | 61349000 |
| Friday, January 1, 2021 | 102802000 | 127125000 |
| Saturday, January 1, 2022 | 102464000 | 136106000 |
| Sunday, January 1, 2023 | 76162000 | 133175999 |
| Monday, January 1, 2024 | 72977000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. CRISPR Therapeutics AG and HUTCHMED (China) Limited, two prominent players in the industry, have shown distinct trends in their SG&A expenses over the past decade.
From 2014 to 2023, CRISPR Therapeutics AG's SG&A costs increased by approximately 1,400%, peaking in 2021. However, a notable reduction of around 26% was observed in 2023, indicating a strategic shift towards cost optimization. In contrast, HUTCHMED's SG&A expenses grew steadily, with a significant 50% rise from 2020 to 2023, reaching their highest in 2022.
This analysis highlights the contrasting approaches of these companies in managing operational costs, offering valuable insights into their financial strategies and market positioning.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.